RLYB
NASDAQ
US
Rallybio Corporation - Common Stock
$8.43
▲ +$0.03
(+0.36%)
Vol 15K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$29.0M
ROE
-25.1%
Margin
-2095.9%
D/E
0.00
Beta
-1.01
52W
$0–$1
Wall Street Consensus
7 analysts · Apr 20260
Strong Buy
0
Buy
4
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
ATOS
Atossa Therapeutics Inc
$76.2M
LSTA
Lisata Therapeutics Inc
$16.4M
ESLA
Estrella Immunopharma Inc
$58.9M
ALGS
Aligos Therapeutics Inc
$57.4M
ATRA
Atara Biotherapeutics Inc
P/E 5.6
$130.4M
LITS
Lite Strategy Inc
$48.6M
SNSE
Sensei Biotherapeutics Inc
$13.5M
CELU
Celularity Inc
$31.6M
CRVO
CervoMed Inc
$73.1M
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.20 | $-1.03 | +$0.17 |
| Sep 2025 | $-1.75 | $-1.12 | +$0.63 |
| Jun 2025 | $-2.00 | $-1.76 | +$0.24 |
| Mar 2025 | $-2.12 | $-1.68 | +$0.44 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -70.6% | -71.7% | -71.7% | -71.7% | -25.1% | -25.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -4576.9% | -5473.3% | -5473.3% | -5473.3% | -2095.8% | -2095.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.98 | 9.98 | 9.98 | 9.98 | 14.74 | 14.74 |
Key Ratios
ROA (TTM)
-23.1%
P/S (TTM)
43.00
P/B
0.6
EPS (TTM)
$-0.32
CF/Share
$-1.80
52W High
$1.08
52W Low
$0.22
$0.22
52-Week Range
$1.08
How does RLYB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RLYB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
43.0
▲
235%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.7
▼
74%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RLYB profitability vs Biotechnology peers
ROE
-25.1%
▲
63%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-2095.9%
▼
631%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-23.1%
▲
51%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
RLYB financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
14.7
▲
232%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-1.0
▼
204%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
RLYB fundamentals radar
RLYB
Peer median
Industry
RLYB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
RLYB vs peers: key metrics
Latest News
No related news yet